According to a new market research report titled, ‘RWE
Oncology Market by Component (Datasets [EHR,
Claims, Cancer Registries], Consulting & Analytics Services), Application
(Drug Development, Approval, Market Access, Post-market Surveillance), and End
User (Pharma, Payer) - Global Forecast to 2029,’ published
by Meticulous Research®, the real-world evidence
oncology solutions market is expected to grow at a CAGR of 14.2% from 2022–2029
to reach $1.65 billion by 2029.
Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5276?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=06-11-2023
Real-world evidence (RWE) is clinical evidence gathered via RWD analysis
on the use and potential benefits or risks of a medical product. RWE can be
produced through various study designs or analyses, including but not limited
to randomized trials, large simple trials, pragmatic trials, and observational
studies (prospective or retrospective). RWE has several applications in
oncology, including drug development life cycles, reducing development
duration, reducing the costs of clinical trials, and improving the probability
of technical and regulatory success. The growth of this market is driven by
factors such as the rising prevalence of cancer, rapidly growing big data in
healthcare, the shift from volume to value-based care, and the rising focus on
personalized healthcare.
The RWE oncology market is segmented based on component (real-world
datasets and RWE consulting & analytics services), application (drug
development & approvals, market access & reimbursement/coverage
decisions, post-market surveillance, medical device development &
approvals, and other applications), end user (pharmaceutical, biotechnology,
and medical device companies, healthcare payers, healthcare providers, and
other end users), and geography (North America, Asia-Pacific, Europe, Latin
America, and the Middle East & Africa). The study also evaluates industry
competitors and analyses the market at the regional and country levels.
Speak to our Analysts to Understand the Impact of
COVID-19 on Your Business: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5276?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=06-11-2023
Based on component, in 2022, the real-world datasets segment is
estimated to account for the largest share of the RWE oncology solutions
market. The large market share of this segment is attributed to the growing
amount of medical data generated in hospitals, increasing dependence on
outcome-based studies on real-world data, and the rising demand for information
regarding drug safety among payers, regulatory bodies, and providers. In
addition, the growing need for evidence generated from real-world data and a
shift from volume to value-based care has resulted in an increased focus on
cancer registries, a rise in the adoption of EHR/EMR in hospitals, and
exponential growth in mobile health data and social media, leading to the
generation of huge amounts of medical data.
Based on application, in 2022, the drug development & approvals
segment is estimated to account for the largest share of the RWE oncology
solutions market. Quality-of-life metrics and Patient-Reported Outcome Measures
(PROMs) are becoming common elements in clinical trials for drug development.
The evidence generated from real-world data is regularly utilized to inform
aspects of drug development, such as the natural history and epidemiology of a disease
and provide data on treatment pathways and comparator interventions in clinical
practice. The rising number of cancer cases has compelled pharmaceutical and
biopharmaceutical companies to focus on drug development for cancer treatment.
The effective deployment of RWE can significantly accelerate the pace of
discovery, enable drug approvals, and help understand the impact of new
oncology therapies, which is expected to drive the growth of this segment.
Quick Buy – “RWE Oncology Market
by Component (Datasets [EHR, Claims, Cancer Registries], Consulting &
Analytics Services), Application (Drug Development, Approval, Market Access,
Post Market Surveillance), End User (Pharma, Payer, Provider) - Global Forecast
to 2029” Research Report: https://www.meticulousresearch.com/Checkout/50669121?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=06-11-2023
Based on end user, in 2022, the pharmaceutical & medical device companies’
segment is estimated to account for the largest share of the RWE oncology
solutions market. The large share of this segment is attributed to the
increasing importance of RWE studies in cancer drug development & approvals
and the growing need to avoid costly drug recalls and assess drug performance
in real-world settings. The healthcare landscape continues to shift from volume
to value-based care and is continuously developing. Pharmaceutical companies
are focusing on new ways to provide the best treatments for cancer patients.
Real-world evidence enables health care professionals and pharmaceutical
companies to understand real-life clinical practices and actual health outcomes
of drugs. Thus, pharmaceutical and biotech companies are increasingly utilizing
real-world evidence to collect real-time post-trial information about drugs,
enabling healthcare providers and researchers to understand the negative
reactions, side effects, and medication errors related to the drugs, thereby
allowing them to control the potential harm caused by the drugs.
Based on Geography, in 2022, North America is estimated to account for
the largest share of the RWE oncology market, followed by Europe, Asia-Pacific,
Latin America, and the Middle East & Africa. The high market growth in
North America is attributed to the increasing number of cancer cases, stringent
regulations for drug approvals, implementation of the 21st Century Cures Act,
increased usage of electronic datasets, advanced healthcare industry, and the
rising amount of big data in healthcare.
The key companies operating in the RWE oncology market are IQVIA
Holdings Inc. (U.S.), ICON plc (Ireland), PPD, Inc. (U.S.), SYNEOS HEALTH, INC.
(U.S.), CLARIVATE PLC (U.S.), Medpace Holdings Inc. (U.S.), Symphony
Innovation, LLC (U.S.), Clinigen Group plc (U.K.), Cognizant Technology
Solutions Corporation (U.S.), Oracle Corporation (U.S.), PAREXEL International
Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.),
UnitedHealth Group Incorporated (U.S.), and Flatiron Health (U.S.).
TOP 10 COMPANIES IN REAL-WORLD
EVIDENCE (RWE) SOLUTIONS MARKET https://meticulousblog.org/top-10-companies-in-real-world-evidence-solutions-market/?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=06-11-2023
Scope of the Report:
RWE Oncology Solutions Market, by Component
- Real-world
Datasets
- Disparate
Datasets
- EMR/EHR/Clinical
Data
- Claims
& Billing Data
- Pharmacy
Data
- Cancer
Registries
- Other
Disparate Datasets
- Integrated
Datasets
- Real-world
Consulting & Analytics Services
(Note: Other Disparate Datasets include data generated from mobile applications, wearable devices, and social media).
RWE Oncology Solutions Market, by
Application
- Drug
Development & Approvals
- Market
Access & Reimbursement/Coverage Decisions
- Post-market
Surveillance
- Medical
Device Development & Approvals
- Other
Applications
(Note:
Other Applications include regulatory and clinical decision-making).
RWE Oncology Solutions Market, by End
User
- Pharmaceutical,
Biotechnology, and Medical Device Companies
- Healthcare
Payers
- Healthcare
Providers
- Other
End Users
(Note:
Other end users include academic research institutions, patient advocacy
groups, regulators, and health technology assessment agencies).
Conti ...
Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5276?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=06-11-2023
Related
Reports:
·
Real-world
Evidence (RWE) Solutions Market by Component (Datasets
[Clinical, Claims, Pharmacy, Integrated], Services), Application (Market
Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma
Companies, Providers) - Global Forecast to 2029 >> https://www.meticulousresearch.com/product/real-world-evidence-solutions-market-4954?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=06-11-2023
·
U.S.
Real-World Evidence (RWE) Solutions Market by Component [Datasets (Clinical, Claims, Pharmacy, Integrated),
Services], Application (Market Access, Oncology, Neurology, Post Market
Surveillance), End User (Pharma Companies, Providers) - Forecast to 2029
>> https://www.meticulousresearch.com/download-sample-report/cp_id=5243
